DK1002108T3 - Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling - Google Patents

Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling

Info

Publication number
DK1002108T3
DK1002108T3 DK98945090T DK98945090T DK1002108T3 DK 1002108 T3 DK1002108 T3 DK 1002108T3 DK 98945090 T DK98945090 T DK 98945090T DK 98945090 T DK98945090 T DK 98945090T DK 1002108 T3 DK1002108 T3 DK 1002108T3
Authority
DK
Denmark
Prior art keywords
mhc class
lag
adjuvant
vaccination
ligands
Prior art date
Application number
DK98945090T
Other languages
English (en)
Inventor
Frederique Triebel
Original Assignee
Roussy Inst Gustave
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Applied Research Systems filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of DK1002108T3 publication Critical patent/DK1002108T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98945090T 1997-07-25 1998-07-23 Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling DK1002108T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97401800A EP0893507A1 (en) 1997-07-25 1997-07-25 Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment

Publications (1)

Publication Number Publication Date
DK1002108T3 true DK1002108T3 (da) 2006-08-21

Family

ID=8229825

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98945090T DK1002108T3 (da) 1997-07-25 1998-07-23 Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling

Country Status (19)

Country Link
US (2) US6410509B1 (da)
EP (3) EP0893507A1 (da)
JP (1) JP4723722B2 (da)
KR (1) KR100603075B1 (da)
CN (1) CN1184320C (da)
AT (2) ATE478956T1 (da)
AU (1) AU753738B2 (da)
BR (1) BR9811037A (da)
CA (2) CA2732570C (da)
DE (2) DE69841866D1 (da)
DK (1) DK1002108T3 (da)
EA (3) EA003740B1 (da)
EE (1) EE200000039A (da)
ES (1) ES2262242T3 (da)
IL (2) IL134212A0 (da)
NO (1) NO20000378L (da)
PT (1) PT1002108E (da)
UA (1) UA75322C2 (da)
WO (1) WO1999004810A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295895B1 (en) * 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
JP5986576B2 (ja) 2010-11-10 2016-09-06 ラボラトリオス レティ，エセ．エレ． 新規アジュバント
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
CN103751778B (zh) * 2014-01-28 2016-09-28 复旦大学 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US10537626B2 (en) 2014-10-07 2020-01-21 Cytlimic Inc. HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
US9827308B2 (en) 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
JP6898225B2 (ja) 2015-03-09 2021-07-07 サイトリミック株式会社 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3797794A1 (en) * 2015-04-07 2021-03-31 Cytlimic Inc. Medicine comprising a toll like receptor 3 agonist and a lag-3 protein
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
EP3349790A1 (en) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
US20230057310A1 (en) * 2018-09-27 2023-02-23 Genocea Biosciences, Inc. Treatment methods
JP2020138940A (ja) 2019-02-28 2020-09-03 テルモ株式会社 治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
WO1990001870A1 (en) * 1988-08-22 1990-03-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Retroviral vectors expressing soluble cd4; a gene therapy for aids
JPH02231083A (ja) * 1988-08-31 1990-09-13 Eisai Co Ltd 組換ナチュラルキラー細胞活性化因子
IL93599A0 (en) * 1989-03-03 1990-12-23 Microgenesys Inc Kit and/or composition for the prevention or treatment of aids
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
SE510135C2 (sv) * 1994-05-05 1999-04-19 Berol Nobel Ab Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
DK0758383T3 (da) * 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
CA2194488A1 (en) * 1994-08-05 1996-02-15 Tod Paul Holler Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
PL320610A1 (en) * 1994-12-07 1997-10-13 Hoffmann La Roche Fragments of monoclonal antibodies of immunosuppressive activity
JPH10511652A (ja) * 1994-12-23 1998-11-10 ラボラトワール・オン・ソシエテ・アノニム 炎症性疾患の予防および／または治療に対するｍｈｃ−ｉｉ結合および／またはｍｈｃ−ｉｉ模倣分子の使用
ES2191784T3 (es) * 1995-12-28 2003-09-16 Univ Johns Hopkins Med Vacunas de tumores de citocinas paracrinas alogenicas.

Also Published As

Publication number Publication date
EA005405B1 (ru) 2005-02-24
EA200000161A1 (ru) 2000-10-30
EP0893507A1 (en) 1999-01-27
KR20010021706A (ko) 2001-03-15
KR100603075B1 (ko) 2006-07-20
WO1999004810A2 (en) 1999-02-04
JP4723722B2 (ja) 2011-07-13
EA003740B1 (ru) 2003-08-28
DE69834330D1 (de) 2006-06-01
ATE478956T1 (de) 2010-09-15
CA2293805A1 (en) 1999-02-04
WO1999004810A3 (en) 1999-07-08
EP1002108A2 (en) 2000-05-24
EP1698701A1 (en) 2006-09-06
IL134212A (en) 2012-03-29
EP1002108B1 (en) 2006-04-26
US6410509B1 (en) 2002-06-25
CA2732570C (en) 2014-11-18
ATE324455T1 (de) 2006-05-15
AU9254798A (en) 1999-02-16
CN1265149A (zh) 2000-08-30
BR9811037A (pt) 2000-08-01
PT1002108E (pt) 2006-09-29
EP1698701B1 (en) 2010-08-25
EA200300092A1 (ru) 2003-06-26
UA75322C2 (en) 2006-04-17
HK1030014A1 (en) 2001-04-20
DE69841866D1 (de) 2010-10-07
CN1184320C (zh) 2005-01-12
NO20000378D0 (no) 2000-01-25
EE200000039A (et) 2000-10-16
IL134212A0 (en) 2001-04-30
EA200200565A1 (ru) 2002-10-31
AU753738B2 (en) 2002-10-24
US20020192195A1 (en) 2002-12-19
NO20000378L (no) 2000-01-25
JP2001510806A (ja) 2001-08-07
CA2732570A1 (en) 1999-02-04
CA2293805C (en) 2011-05-03
DE69834330T2 (de) 2007-03-29
ES2262242T3 (es) 2006-11-16
US7109026B2 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
NO20000378D0 (no) Anvendelse av MHC klasse II ligander som adjuvantia for vaksinasjon og LAG-3 i kreftbehandling
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
BR8300475A (pt) Composto, composicao farmaceutica, processo para tratamento de infeccao virotica em um animal de sangue quente ou de sangue frio, e processo para a preparacao de tal composto
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
ID21529A (id) Metode dan komposisi untuk pengobatan dan pencegahan tumor, gangguan yang berhubungan dengan tumor dan kakeksia
DK16487A (da) Vacciner til oral indgift
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
EP0722324A4 (en) PHARMACEUTICAL COMPOSITION FOR IMMUNITIMULATING THERAPY
CA2034484A1 (en) Radioimmunotherapy using .alpha.-particles emission
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
DE60015084D1 (de) Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
PT845998E (pt) Medicamentos para imunoterapia contendo anticorpos que reconhecem de forma especifica o antigenio mhcii de um paciente a ser tratado
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
DK0983072T3 (da) Fruktanholdige sammensætninger til forebyggelse og behandling af coloncancer
DE68921150D1 (de) Wirkung von hormonen.
EP1037918A4 (en) METHOD AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINALS USING CHEMOKINES
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom
DK188680A (da) Fremgangsmaade til fremstilling af 6-substituerede 11-alkylenmorphantridiner
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
WO2002072013A3 (en) Method of treating malignancies through induction of blood immune responses
BR0212446A (pt) Uso de 4-piridilmetilftalazinas para tratamento de câncer
DK0835309T3 (da) Vaccine imod infektiøse agenser, præparat til behandling og forebyggelse af HIV infektioner
MD950010A (ro) Compoziţie pentru înlăturarea sau dezactivarea componentelor dăunătoare în sînge sau alte lichide extracelulare ale organismului şi procedeu de obţinere